The global hyperparathyroidism therapeutics market is forecast to grow to reach $2.6 billion by 2019. This moderate growth is primarily attributed to the increase in the hyperparathyroidism patient population and the expected launches of two novel drugs: CTAP101 and KAI-4169 IV.

1. Category : Pharma & Healthcare
www.MarketResearchReports.com

2. Introduction to Report
 Launch Date: 31st October, 2012
 Number of Pages: 70
 Geography Coverage: Global
 Available Format: PDF
 Price For Single User License: USD 5,995
 Price For Site User License: USD 11,990
Price For Global User License: USD 17,985
 Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com

3. Scope of the Report:
• Overview of hyperparathyroidism, including
epidemiology, etiology, symptoms, diagnosis,
pathophysiology, management and treatment
guidelines.
• Annualized hyperparathyroidism therapeutics market
revenue, annual cost of therapy and forecast for eight
years to 2019.
• Pipeline analysis: Comprehensive data split across
different phases, emerging trends and mechanisms of
action under development, including calcium sensing
receptor agonist, vitamin D pro-hormone, vitamin D
receptor agonist and CYP24 enzyme inhibitor.
www.MarketResearchReports.com

4. Scope of the Report:
• Analysis of the current and future market competition in
the global hyperparathyroidism therapeutics market.
• Insightful review of the key industry drivers, restraints
and challenges. Each trend is independently
researched to provide qualitative analysis of its
implications.
• Key topics covered include strategic competitor
assessment, market characterization, unmet needs,
clinical trial mapping and implications for the
hyperparathyroidism therapeutics market.
www.MarketResearchReports.com

5. Reasons to Buy..
• Develop and design your in-licensing and out-licensing
strategies through a review of pipeline products and
technologies, and by identifying the companies with the
most robust pipeline.
• Develop business strategies by understanding the
trends shaping and driving the global
hyperparathyroidism therapeutics market.
• Drive revenues by understanding the key trends,
innovative products and technologies, market
segments, and companies likely to impact the global
hyperparathyroidism therapeutics market in future.
• Formulate effective sales and marketing strategies by
understanding the competitive landscape and by
analyzing the performance of various competitors.
www.MarketResearchReports.com

6. Reasons to Buy..
• Identify emerging players with potentially strong
product portfolios and create effective counter-
strategies to gain a competitive advantage.
• Track drug sales in the global hyperparathyroidism
therapeutics market from 2011–2019.
• Organize your sales and marketing efforts by
identifying the market categories and segments that
present maximum opportunities for consolidations,
investments and strategic partnerships.
www.MarketResearchReports.com

7. Report Coverage
Disease Overview
Competitive Assessment
Opportunity and Unmet Need
Pipeline Assessment
Clinical Trials Mapping
Current and Future Players
Licensing and Partnership Deals
Seven Major Markets Overview
www.MarketResearchReports.com

8. Companies Covered:
1. Amgen Inc.
2. Abbott Laboratories
3. Cytochroma Inc.
4. KAI Pharmaceuticals Inc.
www.MarketResearchReports.com

9. How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://www.marketresearchreports.com/globaldata/hype
rparathyroidism-%E2%80%93-analysis-and-market-
forecasts-2019
About Market Research Reports
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +91-8762746600
www.MarketResearchReports.com